Pfizer’s Xalkori for ALK-positive tumors bags FDA’s approval
Pfizer Xalkori, an oral medication for patients suffering from anaplastic lymphoma kinase (ALK) positive lung cancer, has received second nod of approval by the US Food and Drug Administration.